Dartmouth Lung Biology Center for Molecular, Cellular and Translational Research

描述(由申请者提供)：这份Cobre III申请书要求获得资金，以便在达特茅斯的盖泽尔医学院建立一个独立的、国家认可的肺生物学中心(LBC)。Cobre III的拟议计划建立在我们在Cobre I和II期间取得的成功的基础上，在此期间，我们从6名教员组成的核心团队中聚集了32名资金充足、终身教职和终身教职的首席研究人员，他们对呼吸道传染病进行跨学科/多学科研究。我们的LBC教员在宿主-病原体相互作用、呼吸道微生物组以及药物发现和治疗开发方面有着共同的兴趣。为了支持我们的研究，我们建立了三个针对LBC的研究核心，包括：(1)宿主-病原体相互作用核心，(2)活细胞成像核心和(3)翻译研究核心。我们在COBRE 1/11的所有初级教员项目负责人都已经获得了外部资助，在这种资助环境中取得了令人印象深刻的成就。Cobre III奖将提供必要的资源，以促进LBC的持续发展，为加强呼吸道传染病的跨学科/多学科基础科学和翻译研究提供重要资源， 并且是我们的研究核心业务计划的重要组成部分，该计划将在2018年前实现财务独立。COBRE III的支持将促进我们初级教员的持续导师式发展，包括那些以前由COBRE L/ll支持的教员，扩大研究核心和增强试点项目计划，并将促进达特茅斯的导师式、协作和/或翻译研究。再加上达特茅斯的长期承诺，以及与佛蒙特州大学(UVM)肺生物学和免疫学Cobre项目、达特茅斯免疫学Cobre项目、达特茅斯定量生物科学Cobre项目以及加州大学、达特茅斯大学和Mt.在缅因州的荒岛生物实验室(MDIBL)，我们处于异常强大的地位，可以继续巩固我们在宿主-病原体相互作用、CF的呼吸道微生物组研究以及呼吸道传染病的药物发现和治疗开发方面的成功。

DESCRIPTION (provided by applicant): This COBRE III application requests funding to complete the establishment of a free standing, nationally recognized Lung Biology Center (LBC) in the Geisel School of Medicine at Dartmouth. The proposed plan for COBRE III builds upon our successes during COBRE I and II during which time we assembled, from a nucleus of 6 faculty, a critical mass of 32 well funded, tenured and tenure-track principal investigators who conduct inter-/multi-disciplinary research on respiratory infectious diseases. Our LBC faculty share common interests in host-pathogen interactions, the respiratory microbiome, and in drug discovery and therapeutic development. To support the research of our faculty we established three LBC-specific research cores, including a: (1) Host-Pathogen Interaction Core, (2) Live-Cell Imaging Core and (3) Translational Research Core. All of our junior faculty project leaders in COBRE 1/11 have already obtained extramural funding, an impressive record of accomplishment in this funding environment. A COBRE III award will provide essential resources to facilitate the continued development ofthe LBC, provide vital resources to enhance inter/multidisciplinary basic science and translational research in respiratory infectious disease, and is an essential component of our research core business plan to be financially independent by 2018. COBRE III support will enhance the continued mentored development of our junior faculty, including those previously supported by COBRE l/ll, the expansion ofthe research cores and an enhanced Pilot Project Program, and will facilitate mentored, collaborative and/or translational research at Dartmouth. Together with a substantial, and longterm, commitment from Dartmouth and strong collaborative ties with investigators in the Lung Biology and Immunology COBRE programs at the University of Vermont (UVM), the Dartmouth Immunology COBRE, the Dartmouth Quantitative Biological Sciences COBRE, and the INBRE programs at UVM, Dartmouth and the Mt. Desert Island Biological Laboratory (MDIBL) in Maine, we are in an exceptionally strong position to continue to build upon our successes in research on host-pathogen interactions, the respiratory microbiome in CF, and in drug discovery and therapeutic development for respiratory infectious diseases.